EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The prognostic value of IKZF1 plus in B‐cell progenitor acute lymphoblastic leukemia: Results from the EORTC 58951 trial

Michal Kicinski iD, Chloé Arfeuille iD, Nathalie Grardel, Marleen Bakkus, Aurélie Caye-Eude iD, Geneviève Plat, Alina Ferster, Anne Uyttebroeck, Barbara De Moerloose iD, Pierre Rohrlich, Stefan Suciu, Yves Bertrand und 1 weitere

Pediatric Blood & Cancer · 2023

DOI: 10.1002/pbc.30313 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Michal Kicinski und 12 weiteren Autor:innen. Beteiligte Einrichtung: EORTC Headquarters, Brussels, Belgium. Hauptthemen laut MEDLINE: Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

IKZF1 gene deletion is an indicator of poor prognosis in childhood B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL). The AEIOP/BFM group proposed that the prognostic strength of IKZF1 deletion could be remarkably improved by taking into account additional genetic deletions and reported that among patients with an IKZF1 deletion those with deletions in CDKN2A/2B , PAX5 , or PAR1 in the absence of ERG deletion, grouped as IKZF1 plus , had the worst outcome. Procedure Between 1998 and 2008, 1636 patients under 18 years of age with previously untreated BCP‐ALL were registered in the EORTC 58951 trial. Those with multiplex ligation‐dependent probe amplification data were included in this analysis. Unadjusted and adjusted Cox model was used to investigate the additional prognostic value of IKZF1 plus .

Results

Among 1200 patients included in the analysis, 1039 (87%) had no IKZF1 deletion (IKZF1 WT ), 87 (7%) had an IKZF1 deletion but not IKZF1 plus (IKZF1 del ) and 74 (6%) had IKZF1 plus . In the unadjusted analysis, both patients with IKZF1 del (hazard ratio [HR] = 2.10, 95% confidence interval [CI]: 1.34–3.31) and IKZF1 plus (HR = 3.07, 95% CI: 2.01–4.67) had a shorter event‐free survival compared with IKZF1 WT . However, although the IKZF1 plus status was associated with patients’ characteristics indicating poor prognosis, the difference between IKZF1 plus and IKZF1 del was not statistically significant (HR = 1.46, 95% CI: 0.83–2.57, p = .19). The results of the adjusted analysis were similar to the unadjusted analysis.

Conclusions

In patients with BCP‐ALL from the EORTC 58951 trial, the improvement of the prognostic importance of IKZF1 by considering IKZF1 plus was not statistically significant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Burkitt LymphomaPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaAdolescentHumansGene DeletionIkaros Transcription FactorPrognosis

Stichwörter der Autor:innen

B-cell precursor acute lymphoblastic leukemiaIKZF1MLPAprognostic

Substanzen

Ikaros Transcription FactorIKZF1 protein, human

Autor:innen und Institutionen

  • EORTC Headquarters, Brussels, Belgium.
  • Département de Génétique, Hôpital Robert Debré, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France.
  • INSERM, UMR_S1131, Institut de Recherche Saint-Louis, Université Paris-Cité, Paris, France.
  • Haematology laboratory, CHU Lille, Lille, France.
  • Laboratory of Molecular Haematology, University Hospital Brussels, Vrije Universiteit Brussel (VUB), Brussels, Belgium.
  • Department of Hematology, CHU Toulouse, Toulouse, France.

ORCID-Profile: Michal Kicinski, Chloé Arfeuille, Aurélie Caye-Eude, Barbara De Moerloose, Hélène Cavé

Zitieren

APA

Kicinski, M., Arfeuille, C., Grardel, N., Bakkus, M., Caye-Eude, A., Plat, G., Ferster, A., Uyttebroeck, A., De Moerloose, B., Rohrlich, P., Suciu, S., Bertrand, Y., & Cavé, H. (2023). The prognostic value of IKZF1 plus in B‐cell progenitor acute lymphoblastic leukemia: Results from the EORTC 58951 trial. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30313

Vancouver

Kicinski M, Arfeuille C, Grardel N, Bakkus M, Caye-Eude A, Plat G, et al. The prognostic value of IKZF1 plus in B‐cell progenitor acute lymphoblastic leukemia: Results from the EORTC 58951 trial. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30313

BibTeX
@article{Kicinski2023,
  author = {Kicinski, Michal and Arfeuille, Chloé and Grardel, Nathalie and Bakkus, Marleen and Caye-Eude, Aurélie and Plat, Geneviève and Ferster, Alina and Uyttebroeck, Anne and De Moerloose, Barbara and Rohrlich, Pierre and Suciu, Stefan and Bertrand, Yves and Cavé, Hélène},
  title = {The prognostic value of IKZF1 plus in B‐cell progenitor acute lymphoblastic leukemia: Results from the EORTC 58951 trial},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  doi = {10.1002/pbc.30313}
}
Kostenlos starten →